How serious buyers actually screen suppliers

For professional buyers, a complete COA and a clear GMP certificate set often carry more weight than the numbers on a quotation sheet.

In many export projects, Active Pharmaceutical Ingredients (APIs) are still treated as “standard items”: available stock, basic documents, acceptable price – and the box is ticked.

However, Drugdu.com’s trade data show a clear divide:

suppliers that consistently receive high-quality inquiries and progress into registration and tender stages are the ones that treat APIs as the first piece of the supply chain, not just a cost element.

When global buyers evaluate a new project, this is usually where they start.

01. Why is the API the “first piece”?

The API is the source of pharmacological activity, but its role in regulatory and commercial decision-making is much broader.

Each API comes with a full “identity profile”: CAS number, molecular structure, purity, impurity profile, validated process, DMF/CEP status, and more.

Our platform data show that listings with complete, transparent technical and regulatory information convert significantly better, even when they are not the lowest-priced option.

For buyers, the first screening step is to use these visible facts to assess a supplier’s professionalism and reliability.

02. Small molecules vs biologics: different rules

Small-molecule APIs remain the foundation in anti-infective, cardiovascular and diabetes segments. Buyer behaviour here is typically:

identify indication / ATC class;

filter by export qualifications and certifications.

Biologic and highly potent APIs follow a different logic. These products, often used in oncology and autoimmune indications, involve complex processes and high entry barriers.

On Drugdu.com, buyers spend longer on these pages, and the rates of file download, bookmarking and meeting requests are well above average.

In these cases, buyers are no longer asking only “Is there a valid registration?”

They are evaluating the supplier’s overall capability in process development, quality management and compliance.

03. What exactly are buyers checking?

For procurement and regulatory teams, the challenge is less about finding potential suppliers and more about selecting the right ones. Their typical screening funnel has three layers:

Layer 1 – Hard filters

GMP / GDP certifications and audit history

Registration record in target markets

Realistic production capacity and scale

Layer 2 – Documentation & communication

Speed and quality of responses to technical document requests

Clarity on regulatory requirements and change-control topics

Willingness to support samples, technical data and Q&A

Layer 3 – Long-term potential

Readiness to co-invest in registration and variations

Ability to manage supply risks and market volatility

Stability of quality systems and management team

04. From “price tag” to “capability ledger”

One evident trend: suppliers who position APIs only as a price item often stay in pure price competition.

Those who manage APIs as part of a “capability ledger” are building a much stronger position.

This ledger reflects:

Depth and breadth across selected therapeutic areas

cGMP systems that can withstand international inspections, with complete stability and impurity data

The ability to present these strengths clearly to international buyers

On Drugdu.com, suppliers who proactively display a short COA, GMP certificate list and supported registration markets significantly reduce buyers’ initial evaluation time – which directly accelerates project progress.

05. Aligning APIs with real disease patterns

Export performance is increasingly linked to how well a portfolio matches disease burden and policy focus in target markets.

From Drugdu.com inquiry data and exhibition feedback, the following API categories show sustained demand:

Anti-infectives – still core products in tenders across Africa and Southeast Asia

Cardiovascular & metabolic – long-term demand driven by ageing populations

Antivirals – including HIV, HBV and emerging infectious diseases

Oncology & immunology – strong interest in mAb-related APIs and key intermediates

Natural extracts – growing use in nutraceuticals and selected medicinal products

Clearly labelling indications, ATC classes and target markets helps products stand out from a long list of CAS numbers and enter buyers’ shortlists.

For companies expanding internationally, APIs are a condensed version of capability, a starting point of trust, and the foundation of long-term business.

Global buyers are not only looking for a raw-material supplier; they are looking for a partner who can share risk, support registration and maintain stable quality over many years.

At Drugdu.com, we continuously analyse trade data and front-line feedback to make solid API capabilities visible and understandable, and to help turn them into sustainable, mutually beneficial cooperation.